Targeting Type IV Secretion System Proteins to Combat Multidrug-Resistant Gram-positive Pathogens-Reference-Cited by-同舟云学术

Targeting Type IV Secretion System Proteins to Combat Multidrug-Resistant Gram-positive Pathogens

Published:2017-06-15 Issue:12 Volume:215 Page:1836-1845
ISSN:0022-1899
Container-title:The Journal of Infectious Diseases
language:en
Short-container-title:

Author:

Laverde Diana,Probst Ines,Romero-Saavedra Felipe,Kropec Andrea,Wobser Dominique,Keller Walter,Grohmann Elisabeth,Huebner Johannes

Publisher

Oxford University Press (OUP)

Subject

Infectious Diseases,Immunology and Allergy

Link

http://academic.oup.com/jid/article-pdf/215/12/1836/17944256/jix227.pdf

Reference50 articles.

1. The European Centre for Disease Prevention and Control (ECDC) pilot point prevalence survey of healthcare-associated infections and antimicrobial use;Euro Surveill,2012

2. The rise of the Enterococcus: beyond vancomycin resistance;Nat Rev Microbiol,2012

3. Current and prospective treatments for multidrug-resistant gram-positive infections;Expert Opin Pharmacother,2013

4. Management of multidrug-resistant enterococcal infections;Clin Microbiol Infect,2010

5. A type IV-secretion-like system is required for conjugative DNA transport of broad-host-range plasmid pIP501 in gram-positive bacteria;J Bacteriol,2007

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Investigation of cross-opsonic effect leads to the discovery of PPIase-domain containing protein vaccine candidate to prevent infections by Gram-positive ESKAPE pathogens;BMC Microbiology;2024-07-27

2. Silversol® (a Colloidal Nanosilver Formulation) Inhibits Growth of Antibiotic-Resistant Staphylococcus aureus by Disrupting Its Physiology in Multiple Ways;Pharmaceutics;2024-05-28

3. Silversol^®(a colloidal nanosilver formulation) inhibits growth of antibiotic-resistantStaphylococcus aureusby disrupting its physiology in multiple ways;2024-04-23

4. Investigation of cross-opsonic effect leads to the discovery of PPIase- domain containing protein vaccine target to prevent infections by Gram-positive ESKAPE pathogens;2024-03-25

5. Novel TLR4-Activating Vaccine Adjuvant Enhances the Production of Enterococcus faecium-binding Antibodies;Journal of Medicinal Chemistry;2024-03-21